TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 25689936
Drug: Tolvaptan 7.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tolvaptan 7.5 mg
Study: 19007589
Drug: Tolvaptan 15
Normalized name: tolvaptan 15 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tolvaptan 15 mg
Study: 19151304
Drug: 6% hydroxyethyl
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6% hydroxyethyl starch solution
Study: 3531141
Drug: 200 mg/day
Normalized name: alpelisib 200 mg/day (200 mg x 1) ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg/day drug
Study: 3531141
Drug: 200 mg/day
Normalized name: alpelisib 200 mg/day (200 mg x 1) ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg/day drug (tolerance study)
Study: 25581217
Drug: Whole-body vibration
Normalized name: Insects (whole body), mite dermatophagoides farinae
Approvals — FDA: no, EMA: no, PMDA: no
Description: Whole-body vibration (WBV) 0.3g at 37 Hz for 10 minutes daily
Study: 1679047
Drug: Xamoterol (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Xamoterol (200 mg twice daily)
Study: 2572251
Drug: Digoxin (0.125
Approvals — FDA: no, EMA: no, PMDA: no
Description: Digoxin (0.125 mg twice daily)
Study: 22168507
Drug: Computerised cognitive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Computerised cognitive behavioural therapy (CCBT)
Study: 11494079
Drug: Sildenafil (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sildenafil (50 mg initially, increased to 100 mg or decreased to 25 mg based on efficacy and toleration)
Study: 9541846
Drug: Iopentol with
Normalized name: iopentol
DrugBank: Iopentol (DB13861)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Iopentol with 150 mg iodine/ml (viscosity 1.7 mPas, osmolality 340 mOsmol/kg H2O)
Study: 9541846
Drug: High-viscosity radiocontrast
Normalized name: Mineral Oil (high Viscosity)
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-viscosity radiocontrast agents
Study: 10371541
Drug: Gradual dose
Normalized name: MEDICINE DOSE CUP GRADUATED 30ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gradual dose escalation of interferon beta-1b
Study: 10371541
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of ibuprofen treatment and gradual dose escalation of interferon beta-1b
Study: 1768559
Drug: Prochlorperazine (PCZ)
Normalized name: Prochlorperazine
DrugBank: Prochlorperazine (DB00433)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Prochlorperazine (PCZ) 25 mg twice daily for 14 days
Study: 6344550
Drug: Urabe Am
Normalized name: Urate oxidase
DrugBank: Rasburicase (DB00049)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Urabe Am 9 strain of live attenuated mumps vaccine
Study: 31427751
Drug: Immunomodulatory drugs
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immunomodulatory drugs (general)
Study: 21919823
Drug: Subcutaneous alemtuzumab
Normalized name: Alemtuzumab
DrugBank: Alemtuzumab (DB00087)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Subcutaneous alemtuzumab 10 mg three times a week for 18 weeks
Study: 21919823
Drug: Subcutaneous alemtuzumab
Normalized name: Alemtuzumab
DrugBank: Alemtuzumab (DB00087)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Subcutaneous alemtuzumab 30 mg once weekly after lymphocyte count reduction by 1 Log in 18 patients
Study: 7470781
Drug: Amipaque (metrizamide)
Normalized name: metrizamide
DrugBank: Metrizamide (DB01578)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Amipaque (metrizamide) 370 mg iodine/ml
Study: 7470781
Drug: Amipaque (metrizamide)
Normalized name: metrizamide
DrugBank: Metrizamide (DB01578)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Amipaque (metrizamide) 300 mg iodine/ml
Study: 28779269
Drug: Non-heme iron
Normalized name: Heme iron polypeptide
DrugBank: Heme iron polypeptide (DB11067)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-heme iron (FeSO4, 195 mg/day)
Study: 28779269
Drug: Heme iron
Normalized name: HEME IRON
DrugBank: Ferroheme (DB18267)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heme iron (heme-iron-polypeptide, HIP, 31.5 to 94.5 mg/day)
Study: 27129315
Drug: Upper tertile
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Upper tertile U-Cd (≥0.42 μg/g Cr)
Study: 29061084
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (regular physical therapy)
Study: 15598939
Drug: NX (vinorelbine
Approvals — FDA: no, EMA: no, PMDA: no
Description: NX (vinorelbine 25 mg/m(2) days 1 and 8, capecitabine 2000 mg/m(2) days 1‐14, every 21 days)
Study: 10736083
Drug: Rectal codeine
Normalized name: Codeine
DrugBank: Codeine (DB00318)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Rectal codeine phosphate (1 mg.kg‐1)
Study: 10736083
Drug: Intramuscular codeine
Normalized name: Codeine
DrugBank: Codeine (DB00318)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intramuscular codeine phosphate (1 mg.kg‐1)
Study: 1439070
Drug: Isosorbide 5‐Mononitrate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Isosorbide 5‐Mononitrate 50 mg sustained release administered once daily
Study: 31522153
Drug: Combined orthodontic
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined orthodontic regenerative therapy alone (Group II: control group)
Study: 27196567
Drug: Oral ixazomib
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral ixazomib 3 mg
Study: 23231377
Drug: Traditional balance
Normalized name: Rebalance
Approvals — FDA: no, EMA: no, PMDA: no
Description: Traditional balance therapy
Study: 16137243
Drug: Concurrent motor
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Concurrent motor task
Study: 2276321
Drug: 600 mg
Normalized name: mesna 600 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 600 mg calcium supplementation
Study: 22350761
Drug: Pharmacist-assisted medication
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmacist-assisted medication reconciliation
Study: 19850525
Drug: Alteplase (0.9
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alteplase (0.9 mg/kg bodyweight)
Study: 2523870
Drug: ramipril (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: ramipril (5 mg)
Study: 2523870
Drug: captopril (12.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: captopril (12.5 mg)
Study: 25997548
Drug: NRL972 (Fluorescein
Approvals — FDA: no, EMA: no, PMDA: no
Description: NRL972 (Fluorescein Lisicol) 2 mg IV injection
Study: 15195596
Drug: IgY stomat-spray
Normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: IgY stomat-spray (30 doses, 6 times daily, titer = 512)
Study: 11773155
Drug: Overall treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Overall treatment burden estimation using LASA indicators
Study: 9404372
Drug: Frusemide (4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Frusemide (4 ml x 10 mg/ml)
Study: 11519503
Drug: Clopidogrel (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clopidogrel (300 mg immediately, followed by 75 mg once daily)
Study: 26907087
Drug: Creatine monohydrate
Normalized name: Creatine Monohydrate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Creatine monohydrate (CM) 2g daily for 8 weeks
Study: 26907087
Drug: Creatine monohydrate
Normalized name: Creatine Monohydrate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Creatine monohydrate (CM) 4g daily for 8 weeks
Study: 15728066
Drug: Preemptive NSAID
Approvals — FDA: no, EMA: no, PMDA: no
Description: Preemptive NSAID administration
Study: 11804984
Drug: Ramipril 10
Normalized name: ramipril 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ramipril 10 mg per os per day
Study: 11804984
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of estrogens and ramipril
Study: 1646194
Drug: Thoracic megavoltage
Normalized name: Thoracol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thoracic megavoltage radiotherapy preceded and followed by 3 monthly cycles of VCPC (vindesine 1.5 mg/m2 d 1‐2, cyclophosphamide 200 mg/m2 d 2‐4, cisplatinum 100 mg/m2 d 2, lomustine 75 mg/m2 d 3)
Study: 30586700
Drug: Oral Anticoagulation
Normalized name: monitoring agent for oral anticoagulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral Anticoagulation (OAC) alone
Study: 30586700
Drug: Combined OAC
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined OAC and single Antiplatelet Therapy (APT)
Study: 27475283
Drug: C. vulgaris
Approvals — FDA: no, EMA: no, PMDA: no
Description: C. vulgaris (four 300 mg tablets)
Study: 27475283
Drug: Placebo (four
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (four 300 mg tablets)
Study: 19651272
Drug: Electrical stimulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Electrical stimulation therapy (noncycling control group)
Study: 16314627
Drug: Low-dose leucovorin
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose leucovorin plus fluorouracil (Mayo Clinic; LDLV) regimen for 30 to 32 weeks
Study: 16314627
Drug: High-dose leucovorin
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose leucovorin plus fluorouracil (Roswell Park; HDLV) regimen for 30 to 32 weeks
Study: 9630000
Drug: Quetiapine 225
Approvals — FDA: no, EMA: no, PMDA: no
Description: Quetiapine 225 mg bd
Study: 9630000
Drug: Quetiapine 150
Normalized name: quetiapine 150 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Quetiapine 150 mg tid
Study: 9630000
Drug: Quetiapine 50
Normalized name: quetiapine 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Quetiapine 50 mg bd
Study: 3345339
Drug: Nifedipine (orally
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nifedipine (orally administered)
Study: 26614142
Drug: Intrathecal 2.5mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intrathecal 2.5mg hyperbaric levobupivacaine plus 25 μg fentanyl
Study: 21621169
Drug: Institutional-based therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Institutional-based therapy (IT)
Study: 16404099
Drug: No treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: No treatment (CT)
Study: 8770972
Drug: Intravenous calcitriol
Normalized name: Calcitriol
DrugBank: Calcitriol (DB00136)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous calcitriol (2 micrograms) and 3.5 mEq/liter calcium dialysate for six weeks
Study: 6361099
Drug: Medical therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medical therapy (randomizable group)
Study: 6361099
Drug: Surgical therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Surgical therapy (randomizable group)
Study: 30698487
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg pirfenidone
Study: 19140204
Drug: 0.01 mg/kg/d
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.01 mg/kg/d rhIL-18
Study: 19140204
Drug: 0.1 mg/kg/d
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.1 mg/kg/d rhIL-18
Study: 19140204
Drug: 1.0 mg/kg/d
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.0 mg/kg/d rhIL-18
Study: 19140204
Drug: All groups
Normalized name: All Clear
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: All groups (0.01, 0.1, 1.0 mg/kg/d rhIL-18)
Study: 12427437
Drug: No intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: No intravenous glucagon (Control)
Study: 10075343
Drug: 15 g
Normalized name: 15 g/31 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15 g oligofructose/d
Study: 10075343
Drug: sucrose (control
Approvals — FDA: no, EMA: no, PMDA: no
Description: sucrose (control treatment)
Study: 7559195
Drug: Cefotiam hexetil
Normalized name: Cefotiam hexetil hydrochloride
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefotiam hexetil (CTM) 200 mg bd for 5 days
Study: 7559195
Drug: Penicillin V
Normalized name: Penicillin V
DrugBank: Phenoxymethylpenicillin (DB00417)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Penicillin V (PEV) 1 megaunit (600 mg) tds for 10 days
Study: 29709070
Drug: Inactive device
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inactive device (sham treatment)
Study: 25102685
Drug: Western Medicine
Normalized name: Medicaine Sting
Approvals — FDA: no, EMA: no, PMDA: no
Description: Western Medicine (n = 60)
Study: 20708062
Drug: Mandibular 2‐implant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mandibular 2‐implant overdentures (IODs)
Study: 17420340
Drug: Sequential Biventricular
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sequential Biventricular (BiV) pacing
Study: 17420340
Drug: All groups
Normalized name: All Clear
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: All groups (Simultaneous BiV, Sequential BiV, LV pacing)
Study: 15746297
Drug: Intranasal phenoxybenzamine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intranasal phenoxybenzamine
Study: 11978254
Drug: Delayed prescription
Approvals — FDA: no, EMA: no, PMDA: no
Description: Delayed prescription
Study: 11978254
Drug: Immediate prescription
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immediate prescription
Study: 8033492
Drug: Intravenous torsemide
Normalized name: Torsemide
DrugBank: Torasemide (DB00214)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous torsemide
Study: 8033492
Drug: Oral torsemide
Normalized name: Torsemide
DrugBank: Torasemide (DB00214)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral torsemide
Study: 2466880
Drug: Prednisone (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prednisone (20 mg every 8 hours for 48 hours)
Study: 21292168
Drug: Alvimopan (both
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alvimopan (both doses)
Study: 9427984
Drug: 0.2 mg/ml
Normalized name: iodine 0.2 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.2 mg/ml mitomycin-C
Study: 9427984
Drug: 0.4 mg/ml
Normalized name: thymol 0.4 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.4 mg/ml mitomycin-C
Study: 3098341
Drug: 0.025 mg
Normalized name: lisuride 0.025 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.025 mg transdermal oestradiol daily
Study: 3098341
Drug: 0.05 mg
Normalized name: biotin 0.05 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.05 mg transdermal oestradiol daily
Study: 3098341
Drug: 0.1 mg
Normalized name: biotin 0.1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.1 mg transdermal oestradiol daily
Study: 28186933
Drug: Diabetes Medication
Normalized name: Diabetic Tussin EX
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diabetes Medication Choice Decision Aid
Study: 25143179
Drug: Dermatology consultation
Normalized name: benzalkonium
DrugBank: Benzalkonium (DB11105)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dermatology consultation (treatment group)
Study: 15248230
Drug: Etanercept (interrupted
Approvals — FDA: no, EMA: no, PMDA: no
Description: Etanercept (interrupted therapy)
Study: 12508476
Drug: Faropenem 300
Normalized name: Meropenem
DrugBank: Meropenem (DB00760)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Faropenem 300 mg 3 times daily
Study: 2680990
Drug: Enoxacin 400
Normalized name: enoxacin 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enoxacin 400 mg b.i.d. for three days
Study: 31481062
Drug: Parent-group treatment
Normalized name: C.I. direct red 28 parent
Approvals — FDA: no, EMA: no, PMDA: no
Description: Parent-group treatment focusing on evidence-based parenting practices
Study: 16643234
Drug: ILIH block
Normalized name: Ivy Block
Approvals — FDA: no, EMA: no, PMDA: no
Description: ILIH block at 1 cm inferio‐medial to the anterior superior iliac spine (ASIS) with 0.25 ml/kg of 0.25% bupivacaine
Study: 16643234
Drug: ILIH block
Normalized name: Ivy Block
Approvals — FDA: no, EMA: no, PMDA: no
Description: ILIH block at 1-2 cm medial to the ASIS with 0.25 ml/kg of 0.25% bupivacaine
Study: 16643234
Drug: ILIH block
Normalized name: Ivy Block
Approvals — FDA: no, EMA: no, PMDA: no
Description: ILIH block at 2 cm superio‐medial to the ASIS with 0.25 ml/kg of 0.25% bupivacaine
Study: 7988249
Drug: Postoperative thoracic
Normalized name: Thoracol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Postoperative thoracic irradiation plus six cycles of CAP chemotherapy (cyclophosphamide, doxorubicin, and cisplatin)
Study: 7988249
Drug: Postoperative thoracic
Normalized name: Thoracol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Postoperative thoracic irradiation plus six cycles of CAP chemotherapy
Study: 3385548
Drug: Group I:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group I: meperidine intramuscular
Study: 3385548
Drug: Group II:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group II: atropine intramuscular and diazepam intravenous
Study: 26249206
Drug: Insulin (INS,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Insulin (INS, n = 21)
Study: 8175595
Drug: 0.3 g
Normalized name: sorbitol 0.3 GM Oral Lozenge
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.3 g NaHCO3/kg body wt (alkalosis)
Study: 8175595
Drug: 0.04 g
Normalized name: Glycerin 0.04 g in 1 g VAGINAL GEL [Inclear]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.04 g NaCl/kg body wt (control)
Study: 20625264
Drug: HIV-LIPO-5 (all
Approvals — FDA: no, EMA: no, PMDA: no
Description: HIV-LIPO-5 (all doses)
Study: 18664477
Drug: Candesartan (on-treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Candesartan (on-treatment rate <360 fpm)
Study: 18664477
Drug: Candesartan (on-treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Candesartan (on-treatment rate >360 fpm)
Study: 14570722
Drug: 100 micro
Normalized name: Digoxin 100 microgram oral capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 micro g octreotide
Study: 10910488
Drug: Epidural infusion
Normalized name: epidural administration set EPIDURAL INFUSION SETS-PARAPHERNALIA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epidural infusion of ropivacaine 2 mg/ml (group 1)
Study: 10910488
Drug: Epidural infusion
Normalized name: epidural administration set EPIDURAL INFUSION SETS-PARAPHERNALIA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epidural infusion of ropivacaine (both groups)
Study: 8757206
Drug: Albuterol (QID
Approvals — FDA: no, EMA: no, PMDA: no
Description: Albuterol (QID + PRN)
Study: 1558794
Drug: Mitoxantrone (12
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mitoxantrone (12 mg m‐2) administered via a 10 min i.v. infusion to 8 women (10 kinetics)
Study: 1558794
Drug: High-dose mitoxantrone
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose mitoxantrone associated with high-dose alkylating agents administered to 7 women (7 kinetics)
Study: 2862820
Drug: H3R3 (3‐times‐weekly
Approvals — FDA: no, EMA: no, PMDA: no
Description: H3R3 (3‐times‐weekly isoniazid and rifampin up to 6 months)
Study: 2862820
Drug: Patients with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients with drug‐sensitive tubercle bacilli
Study: 15985573
Drug: Testosterone (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Testosterone (100 mg T enanthate, weekly intramuscular injections)
Study: 12974980
Drug: Sufentanil plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sufentanil plus magnesium infusion
Study: 1894763
Drug: Control (aminophylline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (aminophylline 0.9 mg/kg/hr over 6 hours)
Study: 30993680
Drug: Buccally absorbed
Normalized name: COLLAGEN HEMOSTAT,ABSORBABLE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Buccally absorbed prochlorperazine (BAP) 6 mg plus 2.25 mL saline IV placebo
Study: 30993680
Drug: Intravenous prochlorperazine
Normalized name: Prochlorperazine
DrugBank: Prochlorperazine (DB00433)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous prochlorperazine (IVP) 10 mg and buccally absorbed saccharine pill placebo
Study: 30993680
Drug: Intravenous prochlorperazine
Normalized name: Prochlorperazine
DrugBank: Prochlorperazine (DB00433)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous prochlorperazine (IVP)
Study: 19114869
Drug: CD4 cell-driven
Normalized name: lisocabtagene maraleucel
DrugBank: Lisocabtagene maraleucel (DB16582)
Approvals — FDA: no, EMA: no, PMDA: no
Description: CD4 cell-driven scheduled treatment interruption (STI)
Study: 9124839
Drug: Ciprofloxacin (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ciprofloxacin (500 mg)
Study: 7694905
Drug: ECT three
Normalized name: three-lobe sage extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: ECT three times weekly
Study: 7694905
Drug: ECT twice
Normalized name: Tice BCG
DrugBank: Bacillus calmette-guerin substrain tice live antigen (DB10343)
Approvals — FDA: no, EMA: no, PMDA: no
Description: ECT twice weekly
Study: 30242234
Drug: Muscle insulin
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Muscle insulin sensitivity index (MISI)
Study: 30242234
Drug: Hepatic insulin
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hepatic insulin resistance index (HIRI)
Study: 15671129
Drug: Oral risperidone
Normalized name: Risperidone
DrugBank: Risperidone (DB00734)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Oral risperidone 2‐6 mg/day
Study: 29237679
Drug: Pravastatin (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pravastatin (40 mg once daily)
Study: 2502789
Drug: Ethanol (0.56
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ethanol (0.56 g/kg)
Study: 12891223
Drug: Celecoxib (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Celecoxib (200 mg twice daily)
Study: 19920714
Drug: Diclofenac (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diclofenac (50 mg twice daily)
Study: 23945051
Drug: Full-mouth supra-gingival
Normalized name: Supra Sulfa
Approvals — FDA: no, EMA: no, PMDA: no
Description: Full-mouth supra-gingival and sub-gingival non-surgical scaling and root planing, followed by systemic antibiotic therapy, local antiseptics, and oral hygiene instructions.
Study: 12702550
Drug: Interleukin-2 (IL-2)
Normalized name: Fusion protein comprised of a circularly-permuted interleukin-2 (IL-2) with the extracellular domain of IL-2 receptor alpha
DrugBank: Human interleukin-2 (DB14865)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Interleukin-2 (IL-2) 225,000 IU twice daily for 30 days
Study: 8877242
Drug: Ranitidine at
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ranitidine at a dose of 9.3 +/- 0.9 mg/kg/day
Study: 1686656
Drug: 120 mg
Normalized name: papain 120 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 120 mg remoxipride
Study: 6628584
Drug: Becotide inhalation
Normalized name: BECOTIN CAP
Approvals — FDA: no, EMA: no, PMDA: no
Description: Becotide inhalation
Study: 6628584
Drug: Salbutamol pretreatment
Normalized name: salbutamol
DrugBank: Albuterol (DB01001)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Salbutamol pretreatment followed by Becotide inhalation
Study: 31017637
Drug: Rivaroxaban 2.5
Normalized name: rivaroxaban 2.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rivaroxaban 2.5 mg orally twice daily
Study: 30058377
Drug: Micronized dehydrated
Approvals — FDA: no, EMA: no, PMDA: no
Description: Micronized dehydrated human amnion/chorion membrane (dHACM) injection
Study: 21933851
Drug: Chemotherapy-only (intensification
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy-only (intensification and maintenance therapy; n = 186)